DMRA
The table below shows Damora Therapeutics, Inc.'s balance sheet by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $532.90M | $7.61M | $10.21M | $11.94M | $19.68M | $22.86M |
| Short-term investments | - | - | - | - | $11.69M | $11.69M |
| Receivables | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Total current assets |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $535.41M |
| $9.79M |
| $13.03M |
| $14.92M |
| $21.18M |
| $25.17M |
| Property, plant & equipment | - | $41.00K | $47.00K | $52.00K | $62.00K | $67.00K |
| Goodwill | - | - | - | - | - | - |
| Total assets | $535.44M | $10.74M | $13.69M | $15.37M | $23.38M | $27.30M |
| Accounts payable | $819.00K | $520.00K | $756.00K | $354.00K | $503.00K | $724.00K |
| Total current liabilities | $23.81M | $2.62M | $2.63M | $1.55M | $2.44M | $3.71M |
| Long-term debt | - | - | - | - | - | - |
| Total liabilities | $23.84M | $2.73M | $2.74M | $1.66M | $2.44M | $3.71M |
| Retained earnings | -$515.15M | -$286.63M | -$283.49M | -$280.06M | -$270.78M | -$266.90M |
| Total equity | $511.60M | $8.01M | $10.95M | $13.71M | $20.93M | $23.59M |